MyMD Pharmaceuticals (MYMD) Announces Publication of Phase 1 Data for MYMD-1 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Gurugram (Haryana) [India], October 8 (ANI/PRNewswire): Premas Biotech, developer of technologies & bioprocesses for novel proteins, today announced that Oravax Medical Inc., a US-based company that Premas Biotech is a shareholder in, reported positive preliminary data from its Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: - Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed - was observed in 75 per cent of the patients dosed - No safety issues were observed, including mild symptoms Oravax Medical is a clinical-stage vaccine company developing oral vaccines that combine Premas Biotech's D-Crypt Platform with Oramed Pharmaceuticals' POD technology. Oravax's oral Covid-19 vaccine candidate is designed using D-Crypt technology as a triple antigen VLP vaccine that
/PRNewswire/ Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of.
Global Anti-aging Therapeutics Market was valued at US$ 518.86 Million in 2021. It is expected to reach US$ 2013.51 Million by 2030, with a CAGR of 16.53 %
MyMD Pharmaceuticals (MYMD) Announces Data Showing MYMD-1 May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.